Skip to main content

Table 1 Flow analysis of cell cycle in dacomitinib-treated cells.

From: Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

 

UM-UC-6

UM-UC-9

 

DMSO

Dac

DMSO

Dac

24 h

    

G1%

39

81.3

47

56.3

S%

43.8

12.7

36.2

29.9

G2/M%

17.2

6

16.8

13.8

44 h

    

G1%

69.9

77

62.1

79

S%

19.8

16.7

26.7

13.5

G2/M%

10.3

6.3

11.2

7.5

  1. UM-UC-6 and UM-UC-9 cells were analyzed by flow cytometry following a single treatment of 2 µmol/L dacomitinib (Dac) or equivalent concentration of DMSO. The resulting % of gated cells is indicated following 24 h and 44 h of treatment. Differences in UM-UC-6 treated with dacomitinib compared with DMSO were significant at 24 h (p < 0.0001). In UM-UC9 cells, this difference was only significant at 44 h (p = 0.02).